Clinical Trials
Saturday, May 5th, 2012
Circ.ahajournals.org: March 19, 2012. Background—Warfarin is characterized by marked variations in individual dose requirements and a narrow therapeutic window. Pharmacogenetics (PG) could improve dosing efficiency and safety, but clinical trials evidence is meager. Methods and Results—A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II) comprised 2 […]
Clinical Trials
Saturday, April 14th, 2012
The Lancet Neurology, Early Online Publication, April 11, 2012. Background Only 2—5% of patients who have a stroke receive thrombolytic treatment, mainly because of delay in reaching the hospital. We aimed to assess the efficacy of a new approach of diagnosis and treatment starting at the emergency site, rather than after hospital arrival, in reducing […]
Clinical Trials
Saturday, April 14th, 2012
Stroke.ahajournals.org: April 5, 2012. Background and Purpose—Intracranial hemorrhage is the most devastating complication of anticoagulation. Outcomes associated with different sites of intracranial bleeding occurring with warfarin versus dabigatran have not been defined. Methods—Analysis of 18 113 participants with atrial fibrillation in the Randomized Evaluation of Long-term anticoagulant therapY (RE-LY) trial assigned to adjusted-dose warfarin (target international […]
Clinical Trials
Saturday, April 14th, 2012
Stroke.ahajournals.org: April 3, 2012. Background and Purpose—To determine the effect of B vitamin treatment on the incidence of cancer among patients with stroke or transient ischemic attack. Methods—A total of 8164 patients with recent stroke or transient ischemic attack were randomly allocated to double-blind treatment with 1 tablet daily of placebo or B vitamins (2 […]
Clinical Trials
Saturday, April 14th, 2012
Stroke.ahajournals.org: April 3, 2012. Background and Purpose—Desmoteplase is a novel and highly fibrin-specific thrombolytic agent. Evidence of safety and efficacy was obtained in 2 phase II trials (Desmoteplase In Acute Ischemic Stroke [DIAS] and Desmoteplase for Acute Ischemic Stroke [DEDAS]). The DIAS-2 phase III trial did not replicate the positive phase II efficacy findings. Post hoc […]
Clinical Trials
Saturday, April 14th, 2012
Archinte.ama-assn.org: Shikhar Agarwal, MD, MPH, CPH; Rory Hachamovitch, MD, MS; Venu Menon, MD, March 26, 2012. Background Although several new antithrombotic agents have been developed for stroke prevention in patients with nonvalvular atrial fibrillation (AF), many patients will continue to be treated with warfarin worldwide. We performed a meta-analysis of safety and efficacy outcomes in patients with AF treated with […]
Clinical Trials
Sunday, April 8th, 2012
Mdpi.com: April 5, 2012. Atrial Fibrillation (AF) is the most common sustained arrhythmia and 1/6 strokes is attributed to AF. The cornerstone of treatment remains maintaining sinus rhythm or appropriate ventricular rate control in addition to prevention of stroke. Oral anticoagulation therapy (OAC) with vitamin K antagonists (VKAs) has been the gold standard for almost […]
Clinical Trials
Sunday, April 8th, 2012
Content.onlinejacc.org: April 3, 2012. Objectives: The purpose of this study was to characterize patients with mitral regurgitation (MR) and atrial fibrillation (AF) treated percutaneously using the MitraClip device (Abbott Vascular, Abbott Park, Illinois) and compare the results with surgery in this population. Background: The EVEREST II (Endovascular Valve Edge-to-Edge Repair Study) randomized controlled trial compared a […]
Clinical Trials
Sunday, April 8th, 2012
Seniorjournal.com: April, 2, 2012. DCS can speed up word finding in healthy older people and stroke patients; helping to identify which parts of the brain should be stimulated – see video on tDCS in story April, 2, 2012 – A symposium in Chicago explores the possibilities of improving speech, memory and numerical abilities of stroke victims […]
Clinical Trials
Sunday, April 8th, 2012
Reuters.com: By Anna Yukhananov, SILVER SPRING, Maryland | Thu Mar 29, 2012. (Reuters) – Heart safety studies should be required for new obesity drugs, U.S. drug advisers said on Thursday, possibly adding a new hurdle to the drugs’ approval. An advisory panel to the U.S. Food and Drug Administration voted 17-6 that regulators should make companies conduct heart impact […]
